There was much discussion about current research in FAODs at the 2022 International Metabolic conference. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study.
Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals will provide background about the Reneo LC-FAOD clinical study and answer questions.
Date: 08/18/2022Dr. Jan Smeitink